Target General Information
Target ID T74312
Target Name FL cytokine receptor
Synonyms CD135 antigen; FLT3 tyrosine kinase ; Receptor tyrosine kinase FLT3; STK-1; Stem cell tyrosine kinase 1; Tyrosine-protein kinase receptor FLT3; FLT3
Target Type Successful
Gene Name FLT3
Biochemical Class Kinase
UniProt ID FLT3_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease Acute myelocytic leukemia
Example drug Midostaurin Approved [889446], [1572592]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 3.41
Z-score: 4.96
P-value: 2.64E-120
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Alzheimer's disease
Example drug PLX-3397 Phase 3 [525099], [1572592]
Tissue Entorhinal cortex
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.05
Z-score: -0.16
P-value: 2.11E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Psoriasis
Example drug Lestaurtinib Phase 2/3 [537117], [541016], [1572592]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.04
Z-score: 0.11
P-value: 9.51E-04
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.28
Z-score: 0.77
P-value: 3.66E-09
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Breast cancer
Example drug Midostaurin Phase 2 [889446], [1572592]
Tissue Breast tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.16
Z-score: 0.33
P-value: 1.20E-11
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.06
Z-score: -0.12
P-value: 9.28E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Colon cancer
Example drug Midostaurin Phase 2 [889446], [1572592]
Tissue Colon tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.21
Z-score: -0.78
P-value: 1.53E-13
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.31
Z-score: -1.09
P-value: 3.90E-24
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Example drug Tandutinib Discontinued in Phase 2 [541036], [547540], [1572592]
Tissue Brainstem tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.49
Z-score: -0.75
P-value: 4.98E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Glioma
Example drug Tandutinib Discontinued in Phase 2 [541036], [547540], [1572592]
Tissue White matter
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.35
Z-score: -0.75
P-value: 1.15E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Gastric cancer
Tissue Gastric tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.27
Z-score: -0.56
P-value: 7.64E-01
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.07
Z-score: -0.20
P-value: 8.56E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Head and neck cancer
Tissue Head and neck tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.09
Z-score: 0.33
P-value: 1.09E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Myelodysplastic syndromes
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.34
Z-score: -0.58
P-value: 1.71E-02
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 5.15
Z-score: 2.69
P-value: 1.98E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Renal cancer
Tissue Kidney
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.25
Z-score: -0.82
P-value: 1.36E-01
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.41
Z-score: -1.01
P-value: 2.35E-11
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Thyroid cancer
Tissue Thyroid
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.13
Z-score: 0.19
P-value: 5.04E-01
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.06
Z-score: 0.12
P-value: 6.61E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Reference
Ref
Ref 547540Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017148)
Ref 541016(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
Ref 541036(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5695).
Ref 537117Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
Ref 525099ClinicalTrials.gov (NCT02371369) PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS). U.S. National Institutes of Health.
Ref 889446Drugs@FDA (Edaravone)
Ref 1572592NCBI GEO: archive for functional genomics data sets--update.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.